Table 2 Phase 2 studies of newer radiosensitizers alone or combined
From: Radiosensitizers in cervical cancer. Cisplatin and beyond
Schedule [ref] | # pat | Complete R | Survival |
|---|---|---|---|
Gemcitabine 300 mg/m2 (weekly) [95] | -- | 89% | DFS 84%* OS 100% |
Gemcitabine 300–600 mg/m2 days 1, 8, 15, 40, and 47 [96] | 19 | 80% | NR |
Gemcitabine 300 mg/m2 (weekly) [97] | 9 | 89% | DFS 77%** OS 100% |
CDDP 30 mg/m2 + Gemcitabine 20 mg/m2 (both biweekly) [98,99] | 37 | 86% | NR*** |
CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 (both weekly) [100] | 36 | 89% | DFS 81%° |
CDDP 40 mg/m2 | 40 | Path 55% | °° |
Vs | Â | Â | Â |
CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 (both arms weekly) [102] | 43 | Path 77.5% | Â |
CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 both weekly) [104] | 20 | 90% | DFS 80% OS 100%°°° |